StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report released on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
Eiger BioPharmaceuticals Price Performance
Eiger BioPharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $43.35. The company has a market capitalization of $2.55 million, a PE ratio of -0.03 and a beta of 1.83. The stock has a 50-day simple moving average of $5.04 and a two-hundred day simple moving average of $7.14.
Institutional Trading of Eiger BioPharmaceuticals
Hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. grew its stake in shares of Eiger BioPharmaceuticals by 47.4% during the first quarter. Ameriprise Financial Inc. now owns 8,027,532 shares of the biotechnology company’s stock valued at $7,200,000 after purchasing an additional 2,582,776 shares during the last quarter. Barclays PLC grew its stake in shares of Eiger BioPharmaceuticals by 206.7% during the fourth quarter. Barclays PLC now owns 1,615,447 shares of the biotechnology company’s stock valued at $1,907,000 after purchasing an additional 1,088,680 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Eiger BioPharmaceuticals during the fourth quarter valued at approximately $905,000. AQR Capital Management LLC bought a new stake in shares of Eiger BioPharmaceuticals during the fourth quarter valued at approximately $573,000. Finally, RBF Capital LLC bought a new stake in shares of Eiger BioPharmaceuticals during the second quarter valued at approximately $275,000. Institutional investors and hedge funds own 62.46% of the company’s stock.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.
See Also
- Five stocks we like better than Eiger BioPharmaceuticals
- What is a Death Cross in Stocks?
- Comprehensive PepsiCo Stock Analysis
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
